HCV drugs meet SVR goals in late-stage trials, company says

02/6/2013 | Reuters

Two late-stage trials testing nucleotide sofosbuvir in combination with other drugs to treat hepatitis C achieved their sustained virologic response goals in patients, according to drugmaker Gilead Sciences. The therapies were tested in patients with chronic but previously untreated HCV.

View Full Article in:


Published in Brief: